FDA adds NSCLC to Cyramza's label

FDA approved an sBLA under Priority Review from Eli Lilly and Co. (NYSE:LLY) for Cyramza ramucirumab to treat metastatic non-small cell lung cancer (NSCLC).

The approval in combination with docetaxel is for patients whose disease progressed during or after treatment with platinum-based chemotherapy. ...